Global Addisons Disease Treatment Market Insights Forecasts to 2033

• The Global Addison’s Disease Treatment Market Size was Valued at USD 2.56 Billion in 2023
• The Market Size is Growing at a CAGR of 8.93% from 2023 to 2033
• The Worldwide Addison’s Disease Treatment Market Size is Expected to Reach USD 6.02 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Addison’s Disease Treatment Market Size is Anticipated to Exceed USD 6.02 Billion by 2033, Growing at a CAGR of 8.93% from 2023 to 2033.

 

Market Overview

Addison's disease which is also called adrenal insufficiency is a chronic condition in which the adrenal glands, the small triangle-shaped glands located on top of each kidney, do not produce enough cortisol and aldosterone hormones. Cortisol is an important hormone that helps the body respond to stress, and maintain blood pressure, heart function, and immune system. It also regulates the blood glucose levels of an individual. Aldosterone, on the other hand, affects the balance of sodium and potassium in the blood and regulates the elimination of urine. A disorder called secondary adrenal insufficiency occurs when the pituitary gland does not produce enough adrenocorticotropic hormone (ACTH), which stimulates your adrenal glands to produce cortisol. Addison’s Disease treatment can affect people of all ages but is most common in people between 30 and 50 years old.

 

Report Coverage

This research report categorizes the market for the global Addison’s disease treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global Addison’s disease treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global Addison’s disease treatment market.

 

Driving Factors

Addison's disease treatment can improve mood, sexual satisfaction, quality of life, and energy levels by replacing lost hormones. Androgen replacement therapy may improve mood in individuals with the disease, while dehydroepiandrosterone supplementation may improve health-related quality of life in women with adrenal insufficiency. Subcutaneous hydrocortisone can help with daytime energy fluctuations in oral medication users. If the disease is left untreated, Addison’s disease can lead to life-threatening conditions such as a crisis or acute adrenal failure.

 

Restraining Factors

Addison's disease therapy has various drawbacks, including side effects from increased medicine doses and the necessity for frequent checks. Overuse of corticosteroids can cause nausea, sleep disorders, depression, seizures, and menstrual abnormalities. Over-treatment with fludrocortisone can lead to high blood pressure. Glucocorticoid use can lead to osteoporosis, type 2 diabetes, obesity, and hypertension.

 

Market Segmentation

The global Addison’s disease treatment market share is classified into drug class, diagnosis, and treatment.

 

• The glucocorticoids segment is expected to hold the largest share of the global Addison’s disease treatment market during the forecast period.   

Based on the drug class, the global Addison’s disease treatment market is divided into mineralocorticoids, glucocorticoids, and others. Among these, the glucocorticoids segment is expected to hold the largest share of the global Addison’s disease treatment market during the forecast period. This is due to glucocorticoids will replace the cortisol hormone that plays a key role in Addison's disease which individuals with the disease condition do not produce properly. The increasing incidence of Addison's disease and advances in glucocorticoid drugs and administration methods have led to the growth of this segment. In addition, Addison's disease requires lifelong management so the need for ongoing glucocorticoid therapy increases the demand in this area, making it the dominating segment in the treatment landscape of this disease.

 

• The laboratory testing segment is expected to grow at the fastest CAGR in the global Addison’s disease treatment market during the forecast period.   

Based on the diagnosis, the global Addison’s disease treatment market is divided into imaging testing and laboratory testing. Among these, the laboratory testing segment is expected to grow at the fastest CAGR in the global Addison’s disease treatment market during the forecast period. This is mainly due to the importance of blood tests such as serum cortisol and ACTH (adrenocorticotropic hormone) stimulation tests in the early and accurate diagnosis of Addison's disease. As awareness of the disease increases and healthcare infrastructure improves, these laboratory tests are increasingly required for early diagnosis and effective treatment. Also, advances in diagnostic technology and increasing emphasis on drug precision are driving the laboratory testing segment.

 

• The oral corticosteroids segment is expected to grow at the fastest CAGR in the global Addison’s disease treatment market during the forecast period.   

Based on the treatment, the global Addison’s disease treatment market is divided into oral corticosteroids and corticosteroid injections. Among these, the oral corticosteroids segment is expected to grow at the fastest CAGR in the global Addison’s disease treatment market during the forecast period. This improvement is largely driven by the convenience and ease of administration of oral medications, making them the preferred method for long-term illness care. Furthermore, the chronic nature of Addison's disease requires daily prescriptions, and oral corticosteroids are generally more appropriate for continued usage than injectables. Improvements in oral corticosteroid formulations, increased patient adherence and growing diagnosis cases are all contributing to the expected growth of this segment.

 

Regional Segment Analysis of the Global Addison’s Disease Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global Addison’s disease treatment market over the predicted timeframe.

Get more details on this report -

Request Free Sample PDF

North America is anticipated to hold the largest share of the global Addison’s disease treatment market over the predicted timeframe. This dominance is fueled by a well-established healthcare system, a high rate of awareness, increasing diagnosis rates, and the availability of modern diagnostic tools and treatment options. Additionally, major pharmaceutical companies in the U.S. and ongoing R&D activities are boosting the region’s substantial market share. The improved healthcare expenditure and favorable reimbursement policies are fueling the growth of Addison's disease treatment market in this region.

 

Asia Pacific is expected to grow at the fastest pace in the global Addison’s disease treatment market during the forecast period. This great expansion can be attributed to several factors, including increased healthcare spending, greater awareness of adrenal gland disorders, and improved healthcare throughout the region. Furthermore, the growing population, with its increased prevalence of chronic illnesses, enhances the need for early diagnosis and appropriate treatment of Addison's disease. Moreover, government initiatives to improve access to healthcare, and expansion of pharmaceutical services in emerging economies are fueling the rapid growth of the Addison's disease treatment market in the region.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Addison’s disease treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Pfizer Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Shire plc
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• AbbVie Inc.
• Bausch Health Companies Inc.
• Fresenius Kabi AG
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Bayer AG
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In March 2023, Oregon State University College of Engineering developed a handheld sensor capable of testing perspiration for cortisol in just eight minutes, a significant advancement in hormone monitoring.

 

• In December 2023, Neurocrine Biosciences received a Breakthrough Therapy designation from the FDA for its crinecerfont treatment for congenital adrenal hyperplasia.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global Addison’s disease treatment market based on the below-mentioned segments: 

 

Global Addison’s Disease Treatment Market, By Drug Class

• Mineralocorticoids
• Glucocorticoids
• Others

 

Global Addison’s Disease Treatment Market, By Diagnosis

• Imaging Testing
• Laboratory Testing

 

Global Addison’s Disease Treatment Market, By Treatment

• Oral Corticosteroids
• Corticosteroid Injections

 

Global Addison’s Disease Treatment Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa